2-methoxyestradiol
Metastatic Renal Cell Carcinoma
CASI pharmaceuticals, Inc.Small moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 81/ 100
Competitive context
26 Active assets in the Metastatic Renal Cell Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Olaparib Oliver Jonas | Phase 4 | BB |
FILGRASTIM Mayo Clinic | Phase 2 | BB |
Inno-206 Oliver Jonas | Phase 2 | BB |
DEXAMETHASONE University Hospital of Split | Phase 2 | BB |
Zoledronate Kelly Fitzgerald, MD | Phase 4 | BB |
View all 50 →
Same molecule, other indications
2-methoxyestradiol is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →